Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05136014 | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model(OS-TUMOVASC) | unknown | — | 200 | Central Hospital, Nancy, FranceOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05132218 | Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer(EFLRWR) | unknown | — | 180 | Peking University Cancer Hospital & Institute |
| 1 |
| Nov 24, 2021 |
| clinicaltrials |
| NCT05132777 | Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 155 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Nov 24, 2021 | clinicaltrials |
| NCT04405674 | Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC | unknown | Phase 2 | 120 | Shanghai Chest HospitalOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02824952 | Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC | unknown | Phase 2 | 40 | Shaare Zedek Medical CenterOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04000620 | Imaging-based Deep Learning for Lung Cancer Diagnosis and Staging | unknown | — | 500 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05046366 | Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology. | unknown | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05120050 | Clinical Evaluation of ASP Health's Automated ROSE System for Bronchoscopic Applications | unknown | — | 100 | ASP HealthINDUSTRY | 0 | Nov 15, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05117372 | ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS)(LBA-PI) | unknown | N/A | 34 | Centre Chirurgical Marie LannelongueOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT04984148 | Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC | unknown | — | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05073991 | Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR. | unknown | — | 2,224 | Mahidol UniversityOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT05098990 | Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC | unknown | Phase 4 | 328 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT05097417 | Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer | unknown | N/A | 110 | Shanghai 10th People's HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05094167 | Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients | unknown | N/A | 46 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03236675 | Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients | unknown | — | 60 | Exosome Diagnostics, Inc.INDUSTRY | 1 | Sep 30, 2021 | clinicaltrials |
| NCT05055167 | Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05055583 | Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC | unknown | Phase 2 | 30 | Tang-Du HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT04947774 | Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer | unknown | — | 100 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05038007 | Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades | unknown | Phase 2 | 50 | Jannie Bisgaard StæhrOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02929290 | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | unknown | Phase 1 | 80 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02330367 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC | unknown | Phase 1 / Phase 2 | 368 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04291092 | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM | unknown | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT05039905 | SLN Detection With Tc-MSA-ICG in Lung Cancer Patients | unknown | Early Phase 1 | 10 | Korea University Guro HospitalOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04755738 | Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer(MWA) | unknown | Phase 2 | 234 | Qianfoshan HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05034055 | Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer(SKYROCKET) | unknown | Phase 2 | 45 | Yonsei UniversityOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05034133 | Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 20 | Beijing Haidian HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02736513 | Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | unknown | Phase 2 | 40 | Soroka University Medical CenterOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04943029 | Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC(NEOSUN) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT05031533 | Dose-painting Radiation for LA-NSCLC(DPRLC) | unknown | N/A | 46 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04778800 | A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) | unknown | N/A | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 31, 2021 | clinicaltrials |
| NCT05024266 | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma(TACT) | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04375566 | Progressive Web App About Individualized Patient Decision Aid for NSCLC Stage I-II | unknown | — | 45 | Maastricht UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04586465 | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC(DYNAPET) | unknown | Phase 2 | 23 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT00759382 | Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study. | unknown | — | 340 | European Lung Cancer Working PartyOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04465942 | Immunotherapy in Lung Cancer: Treatment After IO Cessation. | unknown | — | 300 | European Lung Cancer Working PartyOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05016544 | Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04964479 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 375 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02731001 | Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer(PRONTOX) | unknown | N/A | 98 | Technische Universität DresdenOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT05010330 | Identify Prognostic Biomarkers of Lung Cancer | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT05008861 | Gut Microbiota Reconstruction for NSCLC Immunotherapy | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04682327 | Gut Microbiota and Cancer Immunotherapy Response | unknown | — | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT05005468 | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.(CAMFA-L) | unknown | Phase 2 | 61 | Shanghai Chest HospitalOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04568291 | CTC in Lung Caner Patients With Bone Metastases | unknown | N/A | 160 | Shanghai 6th People's HospitalOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT05001412 | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | unknown | Phase 1 | 36 | Zhou ChengzhiOTHER | 1 | Aug 12, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Nov 26, 2021source: clinicaltrials